IP59: Kidney Cancer: Epidemiology & Evaluation/Staging/Surveillance I
Sunday, May 17, 2026 9:30 AM to 11:30 AM · 2 hr. (America/New_York)
147A
Poster and Podium Sessions
Oncology: Kidney
Sunday, May 17
IP59-01: Outcomes in the Management of Complex Renal Cysts: Balancing Overtreatment, Cost, and Radiation Exposure
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-02: The Dogma of Why Renal Mass Biopsies Are Not Done: Data from the 2024 AUA Annual Census
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-03: Interim Analysis of a Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients with Clinically Localized Renal Tumors (BIOPSy)
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-04: Radiological assessment of tumor–parenchyma interface for predicting renal parenchymal infiltration or micronodular spread in clear cell renal cell carcinoma
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-05: Refining Surveillance for Small Renal Masses: Predicting Aggressiveness and Oncologic Outcomes Based on Tumour Size and Patient Characteristics
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-06: Sutureless Off-Clamp Robot-Assisted Partial Nephrectomy: Adoption, Learning Curve, and Propensity-Score Matched Outcomes in a Large Single-Center Cohort
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
Rocco Simone Flammia
IP59-07: Surgical Management Optimization and Prognostic Analyses for Sporadic Synchronous Bilateral Renal Cell Carcinoma: A Large-scale Cohort Study
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
Ruiyi Deng · Peking University First Hospital
IP59-08: Tumor Hilar Proximity is Independently Predictive of Recurrence, Cancer-specific survival, Stage, and Grade in Patients with Renal Cell Carcinoma
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-09: Impact of Preoperative GLP-1 Agonist Use on 30-Day Outcomes Following Partial and Radical Nephrectomy in Patients with Kidney Cancer
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-10: Postoperative Outcomes Following Nephrectomy in Overweight Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs)
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-11: A Step Forward in RCC Staging: External Validation of the EAU-Proposed M staging
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-12: A Majority of patients with high grade renal cell carcinoma and early lung recurrence are initially miss-staged
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-13: International Multicentre Insights into the Recurrence Risk of M0 Intermediate-to-High Risk Clear Cell Renal Cell Carcinoma
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-14: Patient and Physician Factors Associated with Adjuvant Pembrolizumab Utilization in the Setting of Surgically Resected Clear Cell Renal Cell Carcinoma
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-15: Postoperative Surveillance in Non-Clear Cell Renal Cancer: Is Current Practice Best Practice?
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-16: Circulating Tumor DNA as a Biomarker for Aggressive Pathology and Oncologic Risk in Localized Clear Cell Renal Cell Carcinoma
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-17: A renal cell carcinoma prognostic Computational Histology Artificial Intelligence (CHAI) biomarker: Development and validation
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-18: Artificial Intelligence Segmentation Algorithm for Venous Tumor Thrombus among Patients with Renal Cell Carcinoma Performs Comparably to Manual Human Segmentation
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
Matthew Mcleay · Mayo Clinic
IP59-19: DIFFERENTIAL PROGNOSTIC MARKERS OF PRIMARY RESISTANCE BETWEEN IO–IO AND IO–TKI THERAPIES IN CLEAR-CELL RENAL CELL CARCINOMA
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-20: Lesion distribution and prognosis of renal cell carcinoma bone metastasis: A novel evaluation model based on random survival forests
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-21: Genetics-driven adaptive management of metastatic clear cell renal cell carcinoma
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-22: Integrative Multi-Omics and Experimental Evidence Reveal Lipid Metabolic Mechanisms Linking Flavoring Additives to Renal Cell Carcinoma
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
Zheng Song
IP59-23: Influence of GLP1 Receptor Agonist on Renal Cell Carcinoma Incidence and Overall Survival, A Propensity Score Matched Analysis Using the OptumLabs Data Warehouse
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-24: Universal Point of Care Germline Testing in Upper Tract Urothelial Carcinoma
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-25: Comparative Performance of EUA and AUA Risk Stratification Models and Development of an Integrated Model for Predicting =pT2 Upper Tract Urothelial Carcinoma: A ROBUUST Analysis
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-26: Preoperative Lymphocyte-to-Monocyte Ratio as a Predictor of Outcome in Non-Metastatic Kidney Cancer: A PRISMA-Compliant Systematic Review and Meta-Analysis.
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-27: Incidence of Adolescent and Young Adult Renal Cell Carcinoma in the Modern Era
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
IP59-28: From the Eyes to the Kidney: Diabetic Retinopathy as a Predictor of Renal Cell Carcinoma
Sunday, May 17, 2026 9:30 AM to 11:30 AM
147A
Registered attendees
KS
Kristian Stensland
Assistant ProfessorUniversity of Michigan